152630-47-2

Basic information

• Product Name: 1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]-4-OXOCYCLOHEXANE-1-CARBONITRILE
• Synonyms: 1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]-4-OXOCYCLOHEXANE-1-CARBONITRILE
• CAS NO: 152630-47-2
• Molecular Formula: C₁₉H₂₃NO₃
• Molecular Weight: 313.39
• EINECS: 427-450-4
• Mol File: 152630-47-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 111-112 °C
• Boiling Point: 498.3°Cat760mmHg
• Flash Point: 216.2°C
• Appearance: /
• Density: 1.16g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.557
• CAS DataBase Reference: 1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]-4-OXOCYCLOHEXANE-1-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]-4-OXOCYCLOHEXANE-1-CARBONITRILE(152630-47-2)
• EPA Substance Registry System: 1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]-4-OXOCYCLOHEXANE-1-CARBONITRILE(152630-47-2)

Safety Data

• Hazardous Substances Data: 152630-47-2(Hazardous Substances Data)

Usage

Complex structure

The compound has a complex structure that includes a cyclopentyl group, a methoxyphenyl group, and a carbonitrile functional group.

Six-membered ring

The compound contains a six-membered ring with a carbonyl group and a nitrile group attached.

Phenyl ring

The compound also contains a phenyl ring that is substituted with a methoxy group and a cyclopentyloxy group.

Potential applications

The presence of these functional groups and rings suggests that this compound may have potential applications in pharmaceuticals, materials science, or other industries.

Further research needed

Further research and analysis would be needed to fully understand the properties and potential uses of this chemical.

Molecular weight

The molecular weight of the compound is approximately 315.4 g/mol.

Appearance

The compound is likely to be a solid at room temperature, although further analysis would be needed to confirm this.

Solubility

The solubility of the compound in various solvents is not known and would require further analysis.

Stability

The stability of the compound under different conditions, such as temperature, pressure, and exposure to light, is not known and would require further analysis.

InChI:InChI=1/C19H23NO3/c1-22-17-7-6-14(12-18(17)23-16-4-2-3-5-16)19(13-20)10-8-15(21)9-11-19/h6-7,12,16H,2-5,8-11H2,1H3

Upstream product

• 152630-49-4 2-carbomethoxy-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexan-1-one 

Downstream Products

• 326008-99-5 methyl 2-chloro-6-cyano-6-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxospiro[2.5]octane-2-carboxylate 
• 350044-42-7 4-(3-cyclopentyloxy-4-methoxyphenyl)-1,4-dicyanocyclohexan-1-ol 
• 164414-71-5 cilomilast 
• 164414-71-5 trans-4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid 
• 153259-65-5 cilomilast 
• 180320-53-0 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1,1-(ethylenedioxy)cyclohexane 
• 153260-04-9 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohex-1-en-1-yl trifluoromethylsulfonate 
• 154284-85-2 cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexyl-1-amine] 
• 153587-26-9 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-one dimethyl ketal 
• 153260-05-0 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexylidene]-1,3-dithiane 
• 153259-62-2 methyl cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylate] 

Relevant articles and documents

CONDENSED HETEROCYCLIC COMPOUNDS AS PDE-IV INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS

The present invention relates to novel heterocyclic compounds that inhibit phosphodiesterase type 4 (PDE4). The compounds are useful for treating inflammatory conditions, diseases of the central nervous system and insulin resistant diabetes , (formula I)

Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids

This invention relates to a method of preparing a compound of the following type by treating a compound of formula (II) with lithium bromide, magnesium bromide and the like.

1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma

Evaluation of a variety of PDE4 inhibitors in a series of cellular and in vivo assays suggested a strategy to improve the therapeutic index of PDE4 inhibitors by increasing their selectivity for the ability to inhibit PDE4 catalytic activity versus the ability to compete for high affinity [3H]rolipram-binding sites in the central nervous system. Use of this strategy led ultimately to the identification of cis-4-cyano-4-[3- (cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid (1, SB 207499, Ariflo(TM)), a potent second-generation inhibitor of PDE4 with a decreased potential for side effects versus the archetypic first generation inhibitor, (R)-rolipram.